Brain MRI Study of Filgotinib Pain Relief in Rheumatoid Arthritis
Studies how filgotinib may ease pain in adults with rheumatoid arthritis using brain scans.
Plain-language title generated from the registry record
Registry title: 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis
Key facts
- Where
- Glasgow, United KingdomSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 74 years old?
Source: NCT05697159, who can take part
Where in United Kingdom
- Neil BasuGlasgow, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NHS Greater Glasgow and Clyde
- Trial code
- NCT05697159
- Record updated
- 14 January 2025
- Original description
This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients.Read full original descriptionShow less
Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis
This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients.
The investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate.
The second is related to peripheral inflammation, specifically joint synovitis, blood cytokines/chemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.
Inclusion: Patients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are:; Adults ≥18 years < 75 years; Right-handed (to reduce neuroimaging heterogeneity).
Exclusion: Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA; Severe physical impairment (e.g. blindness, deafness, paraplegia); Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury; Inability to provide written informed consent; Pregnant or breast feeding; Severe claustrophobia precluding MRI; Contraindications to MRI.